The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: AFP, Alpha Fetoprotein Tumor Marker, Alpha-fetoprotein (AFP), Alphafetoprotein (AFP)
Also known as: Apolipoprotein Evaluation, Apolipoprotein Evaluation Cardio IQ, Cardio IQ Apolipoprotein Evaluation
Also known as: Beta2Microglobulin Serum
Also known as: C-Reactive Protein, CReactive Protein CRP, CRP
Also known as: CA 125 Tumor Marker, CA-125, Cancer Antigen 125, OC125, Ovarian Antigen
Also known as: CA 153, CA-Breast, Cancer Antigen 15-3, Cancer Antigen-Breast
Also known as: CA 199, Carbohydrate Antigen 19-9
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Carcinoembryonic Antigen
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: Thyroxine Binding Prealbumin, Thyroxine-binding Prealbumin, Transthyretin
The Cancer Marker Panel Assessment: Most Common Panel panel contains 11 tests with 65 biomarkers.
The Cancer Marker Panel Assessment is a sophisticated and comprehensive array of diagnostic tests tailored specifically for the intricate task of cancer detection, diagnosis, and monitoring. This panel plays a pivotal role in the realm of oncology, offering a nuanced approach to identifying biomarkers that are closely linked with various types of cancer.
By integrating a variety of tests, including tumor markers, blood chemistry analyses, and specific protein level assessments, this panel provides a detailed snapshot of an individual's potential risk factors and current health status with respect to cancer.
Here's a detailed expansion on how each component of the panel contributes to the multifaceted process of cancer management:
This Cancer Marker Panel Assessment: Most Common Panel encompasses several tests, each targeting different aspects and types of cancer:
Alpha Fetoprotein, Tumor Marker: Used primarily to screen for and monitor liver cancer. It may also indicate the presence of other types of cancer.
Apolipoprotein A1 and B Cardio IQ™: While primarily associated with cardiovascular risk assessment, changes in these proteins can sometimes indicate the presence of cancer.
C-Reactive Protein: An inflammation marker that, when elevated, can suggest the body's response to cancer.
Beta-2-Microglobulin, Serum: This protein level is used to monitor the progression of certain cancers, especially in hematological malignancies.
CA 125: A tumor marker primarily used to monitor therapy during treatment for ovarian cancer and to detect recurrence.
CA 15-3: Most commonly associated with breast cancer, particularly in monitoring treatment response and recurrence.
CA 19-9: Often associated with pancreatic cancer, it's also used in gastric, colorectal, and bile duct cancer monitoring.
CBC (includes Differential and Platelets): Provides a general overview of health and can indicate various conditions, including signs of cancer.
CEA: A marker used in the monitoring of colorectal cancer and other types of cancer.
Comprehensive Metabolic Panel: Offers insights into the health of the body's organs and can indicate complications or effects of cancer.
Prealbumin: A marker of nutritional status which can be affected by cancer.
The SM - Most Common Cancer Markers Panel can aid in the detection and monitoring of several types of cancer, including:
Liver Cancer: The alpha-fetoprotein marker is specifically elevated in most individuals with liver cancer, providing an essential tool for screening and monitoring.
Ovarian Cancer: CA 125 is a key marker for ovarian cancer, useful in diagnosis, treatment monitoring, and detecting recurrence.
Breast Cancer: CA 15-3 serves as a significant marker in the management of breast cancer, particularly for monitoring treatment efficacy and disease progression.
Pancreatic and Gastrointestinal Cancers: CA 19-9 is elevated in pancreatic cancer and can also indicate gastrointestinal tract cancers, aiding in monitoring disease course and response to treatment.
Colorectal Cancer: CEA is primarily used for colorectal cancer, providing valuable information for monitoring treatment response and detecting recurrences.
Hematological Malignancies: Beta-2-Microglobulin levels are useful in assessing disease progression and prognosis in multiple myeloma and other blood cancers.
The Cancer Marker Panel Assessment: Most Common Panel offers a vital resource for early cancer detection, the monitoring of disease progression, and the evaluation of treatment responses. Early detection and continuous monitoring are crucial for improving cancer outcomes, making this panel an invaluable component of modern oncological care. It underscores the importance of a proactive approach to cancer detection and management, embodying a step forward in personalized medicine and patient care.